Scholarlink

Background <p>Anaplastic thyroid carcinoma (ATC) is a rare and highly aggressive malignancy historically associated with a poor prognosis and a median survival of only 3.16 months. However, recent advances in molecular profiling and immunotherapy are improving outcomes.</p> Case presentation <p>We report the case of a 68-year-old man diagnosed with stage IVC ATC who achieved sustained disease stabilisation and long-term survival. Initial treatment with chemotherapy and radiotherapy led to partial remission of the primary tumour, although there was progression of metastatic disease. The patient was subsequently enrolled in a clinical trial investigating an anti-PD-L1 antibody with positive test results, followed by treatment with pembrolizumab. The latter resulted in nearly 11 years of disease control without significant adverse effects, an exceptional outcome in the context of ATC.</p> Conclusion <p>This case underscores the transformative potential of immunotherapy in the management of advanced ATC and highlights the importance of continued research into combinatorial therapeutic strategies and predictive biomarkers to optimise treatment outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A synergistic drug combination that aids our battle against anaplastic thyroid carcinoma: a case report and discussion

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月25日

查看全文
  • Estefanía Chumbiauca,
  • Isabela Valdés Calero,
  • José M. López Picazo,
  • Marta Moreno-Jiménez,
  • Allan Argueta,
  • María D. Lozano,
  • Leonidas Duntas,
  • Juan C. Galofré

摘要

Background

Anaplastic thyroid carcinoma (ATC) is a rare and highly aggressive malignancy historically associated with a poor prognosis and a median survival of only 3.16 months. However, recent advances in molecular profiling and immunotherapy are improving outcomes.

Case presentation

We report the case of a 68-year-old man diagnosed with stage IVC ATC who achieved sustained disease stabilisation and long-term survival. Initial treatment with chemotherapy and radiotherapy led to partial remission of the primary tumour, although there was progression of metastatic disease. The patient was subsequently enrolled in a clinical trial investigating an anti-PD-L1 antibody with positive test results, followed by treatment with pembrolizumab. The latter resulted in nearly 11 years of disease control without significant adverse effects, an exceptional outcome in the context of ATC.

Conclusion

This case underscores the transformative potential of immunotherapy in the management of advanced ATC and highlights the importance of continued research into combinatorial therapeutic strategies and predictive biomarkers to optimise treatment outcomes.